The impact of stress urinary incontinence on sexual activity in women

Matthew D. Barber, MD, MHS
Department of Obstetrics and Gynecology, The Cleveland Clinic Foundation

Sherie A. Dowsett, PhD, BChD
Eli Lilly Research Laboratories, Indianapolis, IN

Karen J. Mullen, MBBS
Lilly Australia, West Ryde, New South Wales

Lars Viktrup, MD, PhD
Eli Lilly Research Laboratories; and Bowen Research Center, Department of Family Medicine, Indiana University School of Medicine, Indianapolis, IN

Address: Lars Viktrup, MD, PhD, Eli Lilly and Company, Faris II, Drop Code 6112, Indianapolis, IN 46285; e-mail Viktrup_lars@lilly.com

Drs. Dowsett, Mullen, and Viktrup are full-time employees of Eli Lilly and Company and are stockholders in the Lilly Company.

Dr. Barber received a $2,000 honorarium for his role as an author of this manuscript.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Matthew D. Barber, MD, MHS
Department of Obstetrics and Gynecology, The Cleveland Clinic Foundation

Sherie A. Dowsett, PhD, BChD
Eli Lilly Research Laboratories, Indianapolis, IN

Karen J. Mullen, MBBS
Lilly Australia, West Ryde, New South Wales

Lars Viktrup, MD, PhD
Eli Lilly Research Laboratories; and Bowen Research Center, Department of Family Medicine, Indiana University School of Medicine, Indianapolis, IN

Address: Lars Viktrup, MD, PhD, Eli Lilly and Company, Faris II, Drop Code 6112, Indianapolis, IN 46285; e-mail Viktrup_lars@lilly.com

Drs. Dowsett, Mullen, and Viktrup are full-time employees of Eli Lilly and Company and are stockholders in the Lilly Company.

Dr. Barber received a $2,000 honorarium for his role as an author of this manuscript.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Matthew D. Barber, MD, MHS
Department of Obstetrics and Gynecology, The Cleveland Clinic Foundation

Sherie A. Dowsett, PhD, BChD
Eli Lilly Research Laboratories, Indianapolis, IN

Karen J. Mullen, MBBS
Lilly Australia, West Ryde, New South Wales

Lars Viktrup, MD, PhD
Eli Lilly Research Laboratories; and Bowen Research Center, Department of Family Medicine, Indiana University School of Medicine, Indianapolis, IN

Address: Lars Viktrup, MD, PhD, Eli Lilly and Company, Faris II, Drop Code 6112, Indianapolis, IN 46285; e-mail Viktrup_lars@lilly.com

Drs. Dowsett, Mullen, and Viktrup are full-time employees of Eli Lilly and Company and are stockholders in the Lilly Company.

Dr. Barber received a $2,000 honorarium for his role as an author of this manuscript.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.